Translation Of PALB2 Genetic Information Into Breast Cancer Clinical Genetic Services
Funder
National Health and Medical Research Council
Funding Amount
$423,081.00
Summary
Today in Australia women attending clinical genetics services and receiving genetic counselling due to a personal and/or family history of breast cancer are not considered for testing of PALB2 despite mounting evidence that the risk of breast cancer in mutation carriers is at least as high as the risk for BRCA2 mutation carriers. This project will provide the evidence base to support the incorporation of PALB2 gene testing into routine clinical genetics services both in Australia and around the ....Today in Australia women attending clinical genetics services and receiving genetic counselling due to a personal and/or family history of breast cancer are not considered for testing of PALB2 despite mounting evidence that the risk of breast cancer in mutation carriers is at least as high as the risk for BRCA2 mutation carriers. This project will provide the evidence base to support the incorporation of PALB2 gene testing into routine clinical genetics services both in Australia and around the world.Read moreRead less
Identification And Characterisation Of A Novel Genetic Signature At The 5p15 Region Associated With Risk Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$610,974.00
Summary
We have recently replicated the genetic association of a region (5p15) with the risk of prostate cancer in Australian men. We now seek to identify the precise genetic variant behind this association, and the functional role of these novel gene/s and variants in disease pathology. Our results will provide a foundation for the development of sensitive and readily applicable lab-based screening tools to be used clinically and will also provide impetus for drug-targeted research by furthering our un ....We have recently replicated the genetic association of a region (5p15) with the risk of prostate cancer in Australian men. We now seek to identify the precise genetic variant behind this association, and the functional role of these novel gene/s and variants in disease pathology. Our results will provide a foundation for the development of sensitive and readily applicable lab-based screening tools to be used clinically and will also provide impetus for drug-targeted research by furthering our understanding on this multifactorial disease.Read moreRead less
Leukaemia, the most common form of childhood cancer, constitutes an important component of Australia's overall cancer burden. We aim to improve our understanding of the genetic and familial contributions to this disease. By establishing the Victorian Paediatric Family Cancer Study, we have evidence of a relationship between maternal age, onset of leukaema and overall risk of cancer in the family. We aim to determine if this finding is genetically based, implying a larger inherited component than ....Leukaemia, the most common form of childhood cancer, constitutes an important component of Australia's overall cancer burden. We aim to improve our understanding of the genetic and familial contributions to this disease. By establishing the Victorian Paediatric Family Cancer Study, we have evidence of a relationship between maternal age, onset of leukaema and overall risk of cancer in the family. We aim to determine if this finding is genetically based, implying a larger inherited component than previously recognized.Read moreRead less
Evolutionary Genomics Approaches For Studying Acquisition Of Drug Resistance In Tumours
Funder
National Health and Medical Research Council
Funding Amount
$313,390.00
Summary
Chemotherapy often fails because some of the cells in tumour evolve resistance to the drugs the patient is given, causing relapse. We study how a tumour’s unstable genome and high rate of mutation drives its evolution by observing tumour cells in the laboratory as they evolve resistance to drugs and the genetic differences between resistant and sensitive cells. This work will help develop therapeutic strategies to prevent tumours from evolving resistance to chemotherapy.
Finding Genetic Risk Markers For Endometrial And Other Cancers
Funder
National Health and Medical Research Council
Funding Amount
$370,668.00
Summary
Studies investigating thousands of genetic markers have revolutionised our understanding of genes involved in cancer. They have also shown that a single gene can be associated with multiple cancers. This project will discover new genes involved in endometrial cancer by detailed genetic analysis, and investigate the genetic similarities between endometrial cancer and different cancers. Results will improve the understanding of cancer and provide opportunity to discover future cancer treatments.
Characterising The Mutations, Signatures, Potential New Therapeutic Targets And Biomarkers In Malignant Mesothelioma Using Whole Genome Analysis.
Funder
National Health and Medical Research Council
Funding Amount
$1,219,288.00
Summary
Malignant mesothelioma is an aggressive tumour that occurs principally in the pleura as a consequence of inhaling asbestos fibres. Currently there is no cure for malignant mesothelioma. Thus new therapeutic approaches are desperately needed. Such new approaches will require a detailed understanding of the genetic lesions of malignant mesothelioma. Therefore we will perform whole genome sequencing of a large cohort of malignant mesothelioma patients to identify mesothelioma-related alterations.
Identification Of Novel Genes Predisposing To Male Breast Cancer, Their Prevalence And Associated Cancer Risks.
Funder
National Health and Medical Research Council
Funding Amount
$210,284.00
Summary
Male breast cancer (MBC) is rare and understudied. Using the latest technology, this study will identify new genes which cause familial MBC to aid in the genetic counselling and risk assessment of an affected man and his family. The frequency of these novel genes, and all known breast cancer genes will be assessed in a second group of affected men as well as families with an increased female breast cancer risk. By better understanding the cause of MBC, we can improve its management.
Interaction Between Moz And PRC1 In Defining Epigenetic States And Gene Expression Patterns
Funder
National Health and Medical Research Council
Funding Amount
$427,271.00
Summary
Regulation of gene expression is implicated in all disease processes. Aberrant gene expression is particularly associated with tumour formation. In this project we determine the relationship between an oncogene MOZ and another oncogene BMI1. Together these proteins regulate one of the most important systems controlling gene expression at the level of chromatin structure.
Immunotherapy In Mismatch Repair-deficient Colorectal Cancers
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
A new drug called PD-1 is effective in treating bowel cancers occurring in people at high risk of cancer called Lynch syndrome but little is known why PD-1 is effective at treating these cancer types. Initial studies have found that certain attributes of these cancers such as high amounts of inflammation may help to predict why these cancers respond to PD-1 but further studies of these tumors are needed to identify other tumor characteristics that may help predict responsiveness to PD-1.